219 related articles for article (PubMed ID: 15336946)
21. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Gupta D; Radhakrishnan M; Kurhe Y
Eur J Pharmacol; 2014 Dec; 744():59-66. PubMed ID: 25284215
[TBL] [Abstract][Full Text] [Related]
22. Role of 5-HT(1A) receptors in fluoxetine-induced lordosis inhibition.
Guptarak J; Sarkar J; Hiegel C; Uphouse L
Horm Behav; 2010 Jul; 58(2):290-6. PubMed ID: 20223238
[TBL] [Abstract][Full Text] [Related]
23. Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography.
Pejchal T; Foley MA; Kosofsky BE; Waeber C
Br J Pharmacol; 2002 Mar; 135(5):1115-22. PubMed ID: 11877317
[TBL] [Abstract][Full Text] [Related]
24. Spinal Serotonin and 5HT6 Receptor Levels During Development of Neuropathy and Influence of Blockade of these Receptors on Thermal Hyperalgesia in Diabetic Mice.
Sari CC; Gunduz O; Ulugol A
Drug Res (Stuttg); 2019 Aug; 69(8):428-433. PubMed ID: 30609433
[TBL] [Abstract][Full Text] [Related]
25. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.
García-Pedraza JÁ; Fernández-González JF; López C; Martín ML; Alarcón-Torrecillas C; Rodríguez-Barbero A; Morán A; García-Domingo M
Life Sci; 2022 Mar; 293():120335. PubMed ID: 35051421
[TBL] [Abstract][Full Text] [Related]
26. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat.
Bristow LJ; O'Connor D; Watts R; Duxon MS; Hutson PH
Neuropharmacology; 2000 Apr; 39(7):1222-36. PubMed ID: 10760364
[TBL] [Abstract][Full Text] [Related]
27. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.
Mayorga AJ; Dalvi A; Page ME; Zimov-Levinson S; Hen R; Lucki I
J Pharmacol Exp Ther; 2001 Sep; 298(3):1101-7. PubMed ID: 11504807
[TBL] [Abstract][Full Text] [Related]
28. Role of central 5-HT(2) receptors in fluoxetine-induced decreases in T lymphocyte activity.
Pellegrino TC; Bayer BM
Brain Behav Immun; 2002 Apr; 16(2):87-103. PubMed ID: 11908920
[TBL] [Abstract][Full Text] [Related]
29. Disruption of 5-HT
Wattiez AS; Dupuis A; Privat AM; Chalus M; Chapuy E; Aissouni Y; Eschalier A; Courteix C
Neuropharmacology; 2017 Oct; 125():308-318. PubMed ID: 28780039
[TBL] [Abstract][Full Text] [Related]
30. 5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats.
Moser PC; Sanger DJ
Eur J Pharmacol; 1999 May; 372(2):127-34. PubMed ID: 10395092
[TBL] [Abstract][Full Text] [Related]
31. Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.
Béïque JC; Blier P; de Montigny C; Debonnel G
Neuropsychopharmacology; 2000 Sep; 23(3):294-306. PubMed ID: 10942853
[TBL] [Abstract][Full Text] [Related]
32. Systemic paracetamol-induced analgesic and antihyperalgesic effects through activation of descending serotonergic pathways involving spinal 5-HT₇ receptors.
Dogrul A; Seyrek M; Akgul EO; Cayci T; Kahraman S; Bolay H
Eur J Pharmacol; 2012 Feb; 677(1-3):93-101. PubMed ID: 22206817
[TBL] [Abstract][Full Text] [Related]
33. Zonisamide: Antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy.
Bektas N; Arslan R; Ozturk Y
Life Sci; 2014 Jan; 95(1):9-13. PubMed ID: 24361360
[TBL] [Abstract][Full Text] [Related]
34. The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice.
Kesim M; Duman EN; Kadioglu M; Yaris E; Kalyoncu NI; Erciyes N
J Pharmacol Sci; 2005 Jan; 97(1):61-6. PubMed ID: 15655293
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors.
Dreshfield LJ; Wong DT; Perry KW; Engleman EA
Neurochem Res; 1996 May; 21(5):557-62. PubMed ID: 8726963
[TBL] [Abstract][Full Text] [Related]
36. LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat.
Mitchell SN; Greenslade RG; Cooper J
Eur J Pharmacol; 2001 Nov; 432(1):19-27. PubMed ID: 11734183
[TBL] [Abstract][Full Text] [Related]
37. Antinociceptive effects of fluoxetine and paroxetine with their related actions on glycemia in mice.
Kesim M; Duman EN; Kadioglu M; Ulku C; Muci E; Kalyoncu NI; Yaris E
Neuro Endocrinol Lett; 2006; 27(1-2):281-7. PubMed ID: 16648811
[TBL] [Abstract][Full Text] [Related]
38. Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy.
Aubel B; Kayser V; Farré A; Hamon M; Bourgoin S
Neuropharmacology; 2007 Feb; 52(2):487-96. PubMed ID: 17027046
[TBL] [Abstract][Full Text] [Related]
39. Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.
Knobelman DA; Hen R; Lucki I
J Pharmacol Exp Ther; 2001 Sep; 298(3):1083-91. PubMed ID: 11504805
[TBL] [Abstract][Full Text] [Related]
40. Greater effects of fluoxetine and its combination with (-)-pindolol in elevating hypothalamic serotonin in rats during dark hours.
Dreshfield LJ; Rocco VP; Wong DT
Chin J Physiol; 1997 Jun; 40(2):57-61. PubMed ID: 9303241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
